Valeant Plans Sales Rep Increase, DTC Campaign For Jublia
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant has something to prove with the launch of Jublia, a topical treatment for toenail fungus, which it has held up as an example of its R&D strategy at work.
You may also be interested in...
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.